Cellectar Biosciences Stock News

Intel Corporation (NASDAQ:INTC) with the stream of -0.41% also noticed, India Cellectar Biosciences, Inc. (NASDAQ:CLRB) encountered a rapid change of -0.86% in the last hour of Fridays trading session. Intel The post Hot Stocks Watch List: Intel Corporation (NASDAQ:INTC), Cellectar Biosciences, Inc. (NASDAQ:CLRB) appeared first on Stocks Equity .

HC Wainwright restated their buy rating on shares of Cellectar Biosciences (NASDAQ:CLRB) in a research report sent to investors on Monday, AnalystRatings.com reports. They currently have a $3.00 price objective on the biopharmaceutical company’s stock. Separately, Zacks Investment Research cut Cellectar Biosciences from a buy rating to a hold rating in a research note on […]

Poster highlighted data from 11 patients with at least triple class refractory multiple myeloma

Cellectar Biosciences (NASDAQ:CLRB)s stock had its buy rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Monday, AnalystRatings.com reports. They presently have a $3.00 target price on the biopharmaceutical companys stock. HC Wainwrights target price suggests a potential upside of 286.10% from the stocks current price. Separately, Zacks Investment Research []

5 penny stocks to watch this week The post Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 penny stocks to watch this week The post Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Cellectar Biosciences, Inc. (NASDAQ:CLRB)s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.04 and traded as low as $0.70. Cellectar Biosciences shares last traded at $0.73, with a volume of 294,634 shares traded. Separately, Zacks Investment Research lowered Cellectar Biosciences from a []

FLORHAM PARK, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercia

CTI BioPharma Corp. (CTIC) with the stream of 5.98% also noticed, India Cellectar Biosciences, Inc. (CLRB) encountered a rapid change of -3.61% in the last hour of trading session. CTI The post Striking Stock: CTI BioPharma Corp. (NASDAQ:CTIC), Cellectar Biosciences, Inc. (NASDAQ:CLRB) appeared first on Stocks Equity .

Vanguard Group Inc. lifted its position in shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) by 14.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,874,584 shares of the biopharmaceutical companys stock after buying an additional 231,180 shares during the quarter. Vanguard Group Inc. owned []

Bumble Inc. (BMBL) with the stream of -4.19% also noticed, India Cellectar Biosciences, Inc. (CLRB) encountered a rapid change of -4.55% in the last hour of Fridays trading session. Bumble The post Up to Date Stock in Focus: Bumble Inc. (NASDAQ:BMBL), Cellectar Biosciences, Inc. (NASDAQ:CLRB) appeared first on Stocks Equity .

Cellectar Biosciences, Inc. (NASDAQ:CLRB) was the target of a large drop in short interest in October. As of October 29th, there was short interest totalling 97,700 shares, a drop of 38.4% from the October 14th total of 158,700 shares. Based on an average daily trading volume, of 518,400 shares, the short-interest ratio is presently 0.2 []

FLORHAM PARK, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that patients in a Phase 1 study of iopofosine I-131 (iopofosine) in children and adolescents with relapsed and refractory high grade gliomas (HGGs) and soft tissue sarcomas, exhibited positive changes in various tumor parameters. The Phase 1 study is an international, open-label, dose escalation, safety study of iopofosine in children and adolescents with relapsed or refractory cancers, specifically HGGs, high risk neuroblastoma and select soft tissue sarcomas.

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has appointed John Friend MD, the former chief medical officer (CMO) at Cellectar Biosciences (NASDAQ:CLRB), Inc as its new CMO.  Dr Friend will be resp

Cellectar Biosciences Inc (NASDAQ: CLRB) has completed part A portion of a safety and tolerability study of iopofosine I-131 (iopofosine) in combination with external beam radiation (EBRT) in relap